-
Regulatory science strategy – public consultation closes on 30 June 2019
Regulatory science strategy – public consultation closes on 30 June 2019
-
Regulatory science strategy – public consultation closes on 30 June 2019
Regulatory science strategy – public consultation closes on 30 June 2019
EMA’s draft ‘Regulatory Science to 2025’ strategy is a plan for advancing EMA’s engagement with regulatory science over the next five to ten years, covering both human and veterinary medicines. Stakeholders have until 30 June 2019 to submit their comments.
-
Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 11-14 June 2019
Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 11-14 June 2019
-
Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 11-14 June 2019
Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 11-14 June 2019
The PRAC starts a new review of leuprorelin medicines after reports of handling errors during preparation and administration.
-
Strengthening engagement between EMA and general practitioners / family physicians
Strengthening engagement between EMA and general practitioners / family physicians
-
Strengthening engagement between EMA and general practitioners / family physicians
Strengthening engagement between EMA and general practitioners / family physicians
EMA, the European Union of General Practitioners (UEMO), the European section of the World Organization of Family doctors (WONCA) and the European Forum for Primary Care (EFPC) sign a joint statement committing to strengthened collaboration.
-
Updated guidance for industry on preparing for Brexit
Updated guidance for industry on preparing for Brexit
-
Updated guidance for industry on preparing for Brexit
Updated guidance for industry on preparing for Brexit
EMA and the European Commission provide additional information to help pharmaceutical companies prepare for the UK’s withdrawal from the EU.
